IND Enabling: Novel Apelin Receptor Agonist (APT101) for Idiopathic Pulmonary Fibrosis (IPF)
NCBiotech Grants & Loans
See the full listing of all NCBiotech grants and loans awarded since July 2012.
Organization
Apie Therapeutics, Inc.
Award Date
Award Amount
250,000
Program Name
Small Business Research Loan
Program Category
Business Financing
Principal Investigator
Esther Alegria
Fiscal Year
2021
Region
Research Triangle
Project Description:
Apie Therapeutics, a spinout of RTI International, is developing Apelin Receptor Agonist drug candidates that target fibrotic diseases. The company's initial indication will be idiopathic pulmonary disease (IDP), a progressive and fatal lung disease. Apie will use the SRL funds to support three IND enabling studies to progress its orally active preclinical lead candidate APT-101 for the treatment of IDP.